Engineered immune cells take aim at Hard-to-Treat leukemia
NCT ID NCT06927466
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This early-stage trial is testing an investigational therapy called B019, which uses a patient's own immune cells engineered to recognize and attack leukemia cells. The study focuses on people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatments. The main goal is to assess the safety and tolerability of B019, while also looking at how well it works and how long any response might last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B019, a CAR-T cell therapy given as an intravenous infusion
- What this could lead to
- If successful, this could lead to a new treatment option that may put leukemia into remission for people who have run out of standard options.
- What could go wrong
- This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause serious side effects, including cytokine release syndrome and neurological issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Shanghai
RECRUITINGShanghai, China
-
Children's Hospital of Soochow University
RECRUITINGSuzhou, China
-
Jiangxi Province pediatric hospital
RECRUITINGNanchang, China
-
Peking University People's Hospital
RECRUITINGBeijing, China
-
Shanghai Children's Medical Center
RECRUITINGShanghai, China
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, China
-
Tongji Hospital
RECRUITINGWuhan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat childhood leukemia
- Supercharged immune cells take on tough B-Cell cancers in early trial
- New drug combo shows promise for tough leukemia cases
- Engineered immune cells take on childhood blood cancers in early trial
- Experimental CAR t therapy targets tough leukemia in first human trial
- New combo therapy shows promise for relapsed leukemia